Cerevel Therapeutics Holdings, Inc.
CEREDelisted Aug 1, 2024- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001805387
Cerevel Therapeutics Holdings, Inc. was delisted on Aug 1, 2024; its insiders filed their last Form 4 on Aug 5, 2024; 231 institutions reported holding it in 13F filings for Q2 2024, worth $6.42B in total; Soros Fund Management was the only superinvestor holding it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 2:22 PM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|
| Period end | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
| Filing | 10-K | 10-K | 10-K | 10-K |
| Reported | – | Feb 22, 2023 | Mar 1, 2022 | Mar 24, 2021 |
| Revenue | $0 | $0 | $0 | $0 |
| Operating expenses | $447.3M | $367.8M | $220.1M | $149.1M |
| Research and development | $334.6M | $280.3M | $161.9M | $103.3M |
| Selling, general and administrative | $112.6M | $87.6M | $58.2M | $45.8M |
| Operating income | -$447.3M | -$367.8M | -$220.1M | -$149.1M |
| Interest expense | $10.6M | $3.92M | – | – |
| Income tax | $503.0K | $160.0K | – | -$24.0K |
| Net income | -$432.8M | -$351.5M | -$225.3M | -$152.1M |
| EPS, basic | $-2.67 | $-2.32 | – | – |
| EPS, diluted | $-2.67 | $-2.32 | – | – |
| Weighted shares, basic | 162.1M | 151.3M | – | – |
| Weighted shares, diluted | 162.1M | 151.3M | – | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|
| Period end | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
| Filing | 10-K | 10-K | 10-K | 10-K |
| Reported | – | Feb 22, 2023 | Mar 1, 2022 | Mar 24, 2021 |
| Cash and equivalents | $416.5M | $136.5M | $193.0M | $383.6M |
| Total current assets | $1.01B | $905.7M | $578.0M | $390.6M |
| Property, plant and equipment | $25.6M | $27.5M | $28.4M | $24.2M |
| Total assets | $1.24B | $1.02B | $688.9M | $445.3M |
| Accounts payable | $11.9M | $10.1M | $11.3M | $4.99M |
| Total current liabilities | $92.2M | $72.6M | $42.5M | $29.5M |
| Long-term debt | $379.5M | $388.1M | – | – |
| Total liabilities | $569.6M | $496.6M | $110.2M | $60.8M |
| Shareholders' equity | $673.7M | $521.2M | $578.7M | $384.5M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|
| Period end | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
| Filing | 10-K | 10-K | 10-K | 10-K |
| Reported | – | Feb 22, 2023 | Mar 1, 2022 | Mar 24, 2021 |
| Operating cash flow | -$342.3M | -$293.2M | -$178.5M | -$117.8M |
| Capital expenditures | $3.81M | $3.95M | $10.5M | $18.9M |
| Free cash flow | -$346.1M | -$297.1M | -$189.0M | -$136.7M |
| Depreciation and amortization | $5.63M | $4.90M | $2.73M | $397.0K |
| Stock-based compensation | $69.4M | $38.8M | $23.9M | $10.5M |
| Investing cash flow | $73.7M | -$388.8M | -$435.7M | -$18.9M |
| Financing cash flow | $548.6M | $623.2M | $423.6M | $440.8M |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Apr 26, 2024 | 182.2M | +16.2% | SEC |
| Mar 31, 2024 | 181.9M | +16.0% | SEC |
| Feb 15, 2024 | 181.6M | +15.9% | SEC |
| Oct 27, 2023 | 180.3M | +15.3% | SEC |
| Jul 28, 2023 | 157.5M | +6.1% | SEC |
| Apr 28, 2023 | 156.8M | +5.8% | SEC |
| Feb 10, 2023 | 156.7M | +5.8% | SEC |
| Oct 28, 2022 | 156.3M | +6.2% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.